Table I.

Summary of OX-40R engagement during tumor priming

Tumor OriginImmunogenicityaTreatmentTumor-Free Mice/Mice Injectedb
MCA 303 (sarcoma)ModeratelymOX-40L:Ig9 /16c
Saline or DR3:Ig0 /16
CT26 (colon carcinoma)ModeratelymOX-40L:Ig9 /24d
hOX-40L:Ige2 /22
SM1 (breast cancer)WeaklymOX-40L:Ig7 /28
Saline1 /28
B16/F10 (melanoma)PoorlymOX-40L:Ig5 /20
Saline0 /20
Anti-OX-40R5 /25
Rat Ig0 /25
  • a The scale for immunogenicity is based on experiments performed in our laboratory or in other laboratories (55). Irradiated cells were injected s.c. into naive recipients and then challenged with live tumor 1–2 wk after immunization. Poorly immunogenic, 0% of the mice survived the challenge; weakly immunogenic, <50% of the mice survived the challenge; and moderately immunogenic, approximately 50% or more of the mice survived the challenge.

  • b Log rank statistical analysis was performed on all groups except for the MCA 303 group and the p values are reported in Results.

  • c Combines all of the experiments where at least 100 μg of mOX-40L:Ig was used.

  • d Combines the two CT26 experiments discussed in Results with different time courses of treatment.

  • e The human (h) OX-40L does not signal the murine OX-40R (42).